• LOGIN
  • SUBSCRIBE
  • FREE E-Newsletter/Product Bulletins

Cath Lab Digest

  • Follow us on
  • Home
  • About Us
    • Privacy Policy/Copyright
    • About VDM
  • Issues
    • Current Issue
    • Issue Archives
  • Editor's Update
  • Advertise
  • Reprints
  • Authors
    • Author Instructions
    • Submission Portal
  • Reviewers
  • Contact

Search

Successful Two-Vessel CTO Intervention: Importance of the Radial Approach

  • Thu, 8/5/10 - 1:22pm
  • 2597 reads
  • 0 comments

Richard R. Heuser, MD, FACC, FACP, FESC, FSCAI and John E. Lassetter, MD, FACC, FSCAI

This 70-year-old gentleman was told his right coronary artery (RCA) had been 100% occluded for 6 years. He presented with continued angina and ischemia not only in the inferior territory but also the lateral territory. His risk factors for coronary disease include hypertension, hyperlipidemia and known chronic occlusion of his RCA for the last 5 to 6 years.

Angiography showed that a total occlusion of the obtuse marginal was present; multiple injections with several catheters were unable to visualize the RCA. There was no antegrade filling of the RCA with multiple catheters. Aortic root injection did not allow visualization of the origin of the vessel. By observing collaterals, it was clear that the RCA was 100% occluded. The patient was enrolled in the FAST CTO study to treat the circumflex artery chronic total occlusion (CTO). With difficulty torqueing the catheter, a long 65 cm Arrow 7 Fr sheath (Arrow International, Cleveland, Ohio) was placed and we used an EBU (Medtronic, Inc., Minneapolis, Minnesota) curve in a Transit catheter (Cordis Corp., Miami Lakes, Florida). After 10 minutes of wiring, we were unsuccessful with a Miracle 3 wire. The CrossBoss was used, and we were able to cross the CTO at first using the Miracle 3 (Abbott Vascular, Abbott Park, Illinois), and then the Fielder XT (Abbott Vascular, Abbott Park, Illinois). Several inflations with a 1.5 x 5 mm balloon were performed, followed by successful placement of several Xience 2.5 x 8 mm, 2.5 x 12 mm, and 2.5 x 12 mm stents (Abbott Vascular). At the end of the procedure, TIMI 3 flow was noted.

The patient was brought back 30 days later for recanalization of the RCA via the right radial artery. A 5 Fr sheath was placed in the left groin, and a diagnostic catheter was placed for simultaneous injections. A JR4 was placed after multiple attempts to visualize the RCA. We were successful with a multipurpose catheter, showing that there was an aberrant takeoff of the RCA with a very straight proximal segment that looked like a bypass graft.

Once the diagnostic study was performed, a Transit catheter was placed, followed by a Miracle 3 wire and then a Fielder XT to cross the 100% occlusion. We exchanged for the Miracle 3 wire to perform balloon angioplasty in several drug-eluting stents with the Xience stents. This 6-year-old occlusion was successfully recanalized.

This is a case where using the radial approach allowed us to visualize the RCA — something that was not possible from the right groin. Our site is now doing radial-first procedures unless there is a contraindication. There has been increasing experience with the radial approach in the treatment of CTOs. In this case, with excellent guiding catheter support, the procedure was actually quite easy, and the CTO was easily recanalized, even though it was 6 years old.

__________________________________________________________________

Richard R. Heuser, MD, FACC, FACP, FESC, FSCAI, is an internationally-recognized cardiologist, inventor, educator and author. A diplomate of the American Board of Cardiovascular Diseases and American Board of Interventional Cardiovascular Diseases, Dr. Heuser is one of the early pioneers of angioplasty and is considered one of America’s top cardiologists. Dr. Heuser is currently in practice at the Phoenix Heart Center/Physicians Group of Arizona. He is Chief of Cardiology and Chief of Cardiac Catheterization Laboratory at St. Luke’s Hospital and Medical Center, Phoenix, Arizona, and Clinical Professor of Medicine at the University of Arizona College of Medicine, as well as Director of the Interventional Fellowship Program at the University of Arizona College of Medicine, Phoenix Campus.

With 13 patents granted for different catheters, stents and other medical devices, Dr. Heuser has served as principal investigator to research the safety and/or effectiveness of more than 100 medical devices and 70 pharmaceutical products, and has participated in more than 150 research studies. He has authored over 400 articles, textbooks and medical manuscripts, and is frequently invited to international medical conferences to present the findings of research developed in Phoenix.

Dr. Heuser received his medical degree from the University of Wisconsin School of Medicine in Madison, Wisconsin, and completed his medicine internship and residency, as well as his cardiology fellowship, at The Johns Hopkins Hospital in Baltimore, Maryland.

image description image description
Opinions expressed by authors, contributors, and advertisers are their own and not necessarily those of HMP Communications, the editorial staff, or any member of the editorial advisory board. HMP Communications is not responsible for accuracy of dosages given in articles printed herein. The appearance of advertisements in this journal is not a warranty, endorsement or approval of the products or services advertised or of their effectiveness, quality or safety. HMP Communications disclaims responsibility for any injury to persons or property resulting from any ideas or products referred to in the articles or advertisements.


Post new comment

  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

More information about formatting options

Image CAPTCHA
Enter the characters shown in the image.

  • Advertise your Job Here
    For information on posting classified ads, please contact:
    Alex Dulnikowski, Classified Sales Manager
    (800) 237-7285, ext. 205

vdm Blogs

PROTECT carotid stent trial provides further evidence that CAS is getting better and becoming more competitive with CEA

Frank J Criado MD FACS FSVM

A New Algorithm to Treat Patients with Peripheral Vascular Disease

Robert S. Dieter MD RVT and Aravinda Nanjundappa MD RVT

In-Stent Restenosis in the SFA Remains a Significant Unresolved Problem

Frank J Criado MD FACS FSVM

Support Comes From Many Directions

Richard R. Heuser MD FACC FACP FESC FSCAI

Pedal Artery Access: Advances in Management of Critical limb ischemia

Robert S. Dieter MD RVT and Aravinda Nanjundappa MD RVT
more »

Vascular Newswire

  • Boston Scientific Launches Innovative Crossing Device to Treat Complete Blockages in Peripheral Arteries
    Fri, 02/10/12 - 11:12am
  • Stereotaxis Announces European Adoption Milestone and Health Canada Market Clearance for Vdrive System
    Fri, 02/10/12 - 11:08am
  • Medtronic Stent Resulted in 90% Freedom from Reinterventions in Narrowed Leg Arteries at 12 Months in International Study
    Thu, 02/09/12 - 10:52am
  • AngioDynamics Launches DuraFlow 2 Chronic Hemodialysis Catheter
    Wed, 02/08/12 - 10:18am
more »

Clinical Events Calendar

  • American Venous Forum 24th Annual Meeting
    Wed, 02/08/2012 - Sat, 02/11/2012
    Orlando, FL, United States
  • JIM 2012
    Thu, 02/09/2012 - Sat, 02/11/2012
    Rome, Italy
  • Cardiovascular Care Update 2012 (CVC)
    Fri, 02/10/2012 - Sat, 02/11/2012
    Scottsdale, AZ, United States
more »

Poll

How do you feel about the continued practice of screening patients for asymptomatic CAD?:
REVIEW OUR OTHER Cardiology BRANDS

Our other resources for healthcare professionals.

HMP Communications © 2012 HMP Communications

HMP Communications LLC (HMP) is the authoritative source for comprehensive information and education servicing healthcare professionals. HMP’s products include peer-reviewed and non-peer-reviewed medical journals, national tradeshows and conferences, online programs and customized clinical programs. HMP is a wholly owned subsidiary of HMP Communications Holdings LLC. ©2012 HMP Communications